KeyBanc analyst Brett Fishbin lowered the firm’s price target on ResMed (RMD) to $268 from $280 and keeps an Overweight rating on the shares. The firm believes underlying MedTech trends remain mostly positive heading into Q1 earnings season, but is lowering several price targets to reflect macro concerns around the potential impact of tariffs as well as an increased risk of recession.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RMD:
- RMD Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- ResMed price target lowered to $265 from $280 at Mizuho
- Resmed’s Strong Financial Performance and Strategic Growth Drive Buy Rating
- Positive Outlook for Resmed Inc: Buy Rating Despite Short-Term Challenges
- ResMed placed on ‘downside 90-day catalyst watch’ at Citi